A hit on one goal helps, but future Nash data will be more decisive.
The company follows Madrigal and Akero with a clinical hit.
The next few months will see some important mid-stage Nash results, from Viking, 89Bio, Northsea and others.
The Nash pipeline is pharmacologically diverse, and some projects look like very long shots.
Calliditas heads for confirmatory data in IgA nephropathy, while Viking and 89Bio are set for key readouts in Nash.
The group gets a win in severe hypertriglyceridaemia, but a bigger readout in Nash awaits.
At the US liver conference Inventiva will make a case for PPAR agonism, while Novo Nordisk and Gilead’s combo will be scrutinised in Nash.